Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The latest spat over the potential approval of aducanumab, an amyloid-β-targeting drug for Alzheimer’s disease, highlights continuing controversy over the amyloid-β hypothesis.
